Intravesical Therapies in Non-muscle Invasive Bladder Tumors
Journal Title: Üroonkoloji Bülteni - Year 2019, Vol 18, Issue 1
Abstract
In the European Association of Urology (EAU) 2015 Guidelines for non-muscle invasive bladder tumors, maintenance Bacillus Calmette-Guérin (BCG) therapy is a grade A recommendation. In the intermediate-risk group, re-evaluation is recommended after 1-year full-dose treatment; in the highrisk group, full-dose BCG is recommended for 1-3 years. Intravesical BCG therapy fails in 40% patients in an average of 2 years. In these cases, there is no alternative treatment that is considered effective. In patients with failed BCG, comparison of BCG and gemcitabine showed less recurrence in the long term with gemcitabine while progression and toxicity were similar. Early radical cystectomy should be considered in non-muscle invasive bladder cancer patients with BCG-refractory T1G3 who have good performance status and low comorbidity. In T1 tumors, invade deeper than 3 mm and/or larger than 6 mm in diameter has been associated with a 100% progression rate. BCG decreased recurrence more significantly in high-risk Ta and T1 tumors. In terms of progression of high-risk superficial bladder cancer, comparison of mitomycin C and BCG showed that BCG is superior if maintenance therapy is given. EAU guidelines recommend early bladder chemotherapy instillation (EBCI), in the low-to-intermediate risk group. There was no clear effect of EBCI in the intermediate- and high-risk group. EBCI alone reduces recurrence only in the low-risk group. However, adjuvant intravesical chemotherapy (AIVC) is recommended in the intermediate- and high-risk groups because it improves relapse-free survival. BCG and maintenance BCG therapy were found to be more effective than AIVC in reducing progression and preventing recurrence.
Authors and Affiliations
Serdar Geyik
Keywords
Related Articles
- EP ID EP550869
- DOI 10.4274/uob.galenos.2018.1116
- Views 111
- Downloads 0
Renal Function Deterioration After Radical Cystectomy and Analysis of Predictive Factors for Renal Deterioration
Objective: Renal function deterioration develops in most of the patients treated with radical cystectomy (RC). In this study, we aimed to evaluate the changes in renal function of bladder cancer (BC) patients who had min...
Gleason Score Correlation Between Prostate Biopsy and Radical Prostatectomy Specimens
Objective: Prostate cancer is the most common malignancy in men and the second cause of cancer-related mortality. Prostate biopsy and the Gleason score guide treatment decisions in prostate cancer. Several studies have i...
Targeted Agents and Resistance Mechanism in Renal Cell Cancer
Renal cell carcinoma (RCC) exhibits multidrug resistance protein P-glycoprotein expression due to the proximal tubular origin and in this regard, it is resistant to a large number of cytotoxic chemotherapy. The identific...
The Optimum Dosage of Prilocaine in Periprostatic Nerve Block During Transrectal Ultrasound Guided Prostate Biopsy: A New Approach in Dose Calculation
Objective: We aimed to calculate the optimum dose of prilocaine per one mL prostate volume in periprostatic nerve block (PPNB) during transrectal ultrasound (TRUS) guided prostate biopsy (PBx). Materials and Methods: We...
Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy
Recently, prostate-specific membrane antigen (PSMA), a glutamate carboxypeptidase II enzyme, has transformed intoan excited radiopharmaceutical agent as a result of radiolabeling of small peptides that are developed for...